Theranos Fails the Test
Theranos’ precipitous fall offers lessons for NewCos and their investors. A Conversation piece by Norman A. Paradis, professor of medicine at Dartmouth, includes all the usual we-should-have-seen-it-coming roundup of the facts. But near the end of Paradis’s article is one crucial warning sign that even those not steeped in the world of medical devices should have caught. Theranos insisted it had to operate in extended stealth mode to keep a competitive advantage, which meant it didn’t publish peer-reviewed studies. In other words, you had to trust. You couldn’t verify. This fact was further compounded by a lack of anyone with deep knowledge of medical testing on Theranos’ board. That will likely turn out to be a disaster for the investors. We’ll never know what the company could have learned and corrected for had it followed a more open approach.
A Country of Two Cities
Well, two kinds of cities, anyway. American cities grow in one of two ways: up or out (Fast Company), according to an analysis by contractor broker Buildzoom. Cities that stop expanding get too expensive for most people (hello, San Francisco!); cities that sprawl keep housing prices under control as the notion of a city center turns more diffuse.